5-Fluorouracil, Leucovorin, Ifosfamide and Cisplatin (FLIP) Combination Chemotherapy for Adevanced Non-Small Cell Lung Cancer.
- Author:
Hyun Sik JEONG
1
;
Keunchil PARK
;
Jung Ae LEE
;
Young Iee PARK
;
In Sook WOO
;
Ki Suk JUNG
;
Young Suk PARK
;
Duk Jhe SHUN
;
Won Seog KIM
;
Jeong A KIM
;
Sung Soo YOON
;
Won Ki KANG
;
Hong Ghi LEE
;
Chan Hyung PARK
Author Information
1. Division of Hematology & Oncology, Department of Internal Medicine, Samsung Medical Center, Korea.
- Publication Type:Original Article
- Keywords:
Lung;
5-Fluorouracil;
Leucovorin;
Ifosfamide;
Cisplatin
- MeSH:
Agranulocytosis;
Anemia;
Carcinoma, Non-Small-Cell Lung*;
Cisplatin*;
Disease Progression;
Drug Therapy;
Drug Therapy, Combination*;
Female;
Fluorouracil*;
Follow-Up Studies;
Humans;
Ifosfamide*;
Leucovorin*;
Lung;
Male;
Nausea;
Stomatitis;
Vomiting
- From:Journal of the Korean Cancer Association
1997;29(1):46-52
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To evaluate the response rate and toxicity of combination chemotherapy including 5-fluorouracil (F), leucovorin (L), ifosfamide (I) and cisplatin (P) for the previously untreated patients with unresectable stage IIIB or IV non-small cell lung cancer. MATERIALS AND METHOD: The doses of FLIP were 5-fluorouracil 800 mg/m2 CI days 1-5, leucovorin 20 mg/m2 IV days 1-5, ifosfamide 1000 mg/m2 CI days 1-3, cisplatin 100 mg/m2 IV day 1 respectively. Cycles were repeated every 3 weeks until disease progression. Seventy-three previously untreated patients were enrolled. Age ranged from 30 to 73 (median 56 years); 43 were male, 30 female. Fifty-three patients had performance status (ECOG) 0-1 and 19 performance status 2. Twenty-two patients had stage IIIB and 51 stage IV. Follow-up ranged from 7+ to 160weeks (median 57 weeks). RESULTS: The overall response rate was 46.7% for 62 evaluable patients. (CR 1 patient, PR 28 patients) Median response duration was 24 weeks (range 1+ to 36+ weeks). Toxicity > Grade II (WHO) included: granulocytopenia 19.8%, anemia 13.5%, nausea and vomiting 31.5% stomatitis 46.5%, neuropathy 24.6%. CONCLUSION: FLIP chemotherapy was comparable to other combination chemotherapy for advanced non-small cell lung cancer with moderate toxicities.
